Previous Close | 0.5400 |
Open | 0.5322 |
Bid | 0.5645 x 100 |
Ask | 0.6368 x 100 |
Day's Range | 0.5300 - 0.6100 |
52 Week Range | 0.1330 - 0.9900 |
Volume | |
Avg. Volume | 193,172 |
Market Cap | 16.321M |
Beta (5Y Monthly) | 0.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3800 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Continuous blood glucose monitor’s preclinical data and sensor longevity modeling to be presented at major diabetes conference Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been accepted for poster presentation at the American Diabetes Association (ADA) 84th Scienti
In a recent transaction filed with the SEC, Drew Sycoff, serving as a Director and 10% Owner, has purchased 182,540 shares of GlucoTrack Inc (NASDAQ:GCTK) on April 22, 2024.
Rutherford, NJ, April 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that the Company has closed a private placement of securities. The Offering included participation by CEO Paul V. Goode, PhD, as well as other members of the Company’s executive management, Board of Directors, and existing shareholders.